BridgeMD
Tests treatment safety and results for Hypertension,Essential
Official title Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial
ClinicalTrials.gov ID: NCT06093932
What this study is testing
What is Songling Xuemaikang Capsules?
Songling Xuemaikang Capsules is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for hypertension,essential.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is: 1. To evaluate the efficacy of Songling Xuemaikang Capsules(SLXMKC) with grade 1 hypertension.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 35 to 65
You may be able to join if
- Age between 35-65 years old, male or female;
- Grade 1 essential hypertension;
- Taking no antihypertensive drugs or taking antihypertensive drugs irregularly in the past ;
- Sign the informed consent;
You likely can't join if
- Significant liver and kidney dysfunction, ALT and AST upper the twice of normal range, Scr≥2.0mg/dl, eGFR\<60ml/(min 1. 73m2);
- Gastrointestinal diseases, which may affect drug absorption;
- Be allergic to the clinical trial medicine;
- Pregnant or breastfeeding women, men who plan to give birth within half a year;
- Combined with other serious primary diseases or malignant tumors;
- Hyperlipidemia with or without taking lipid-lowering drugs;
See the full eligibility criteria
- Age between 35-65 years old, male or female;
- Grade 1 essential hypertension;
- Taking no antihypertensive drugs or taking antihypertensive drugs irregularly in the past ;
- Sign the informed consent;
- Significant liver and kidney dysfunction, ALT and AST upper the twice of normal range, Scr≥2.0mg/dl, eGFR\<60ml/(min 1. 73m2);
- Gastrointestinal diseases, which may affect drug absorption;
- Be allergic to the clinical trial medicine;
- Pregnant or breastfeeding women, men who plan to give birth within half a year;
- Combined with other serious primary diseases or malignant tumors;
- Hyperlipidemia with or without taking lipid-lowering drugs;
- Combined with left ventricular hypertrophy, ABI \< 0.9, CIMT ≥ 0.9mm or atherosclerotic plaque;
- Hypertensive comorbidities (cerebrovascular disease, other cardiovascular diseases, renal disease, peripheral artery disease, retinopathy, diabetes);
- Other serious conditions in which is not fit for the study.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
- Suzhou, Jiangsu, China
- Jinan, Shandong, China
- Jining, Shandong, China
- Taiyuan, Shanxi, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 35 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China; Suzhou, Jiangsu, China; Jinan, Shandong, China; Jining, Shandong, China; Taiyuan, Shanxi, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.